Malignant Neoplasms
|
0.400 |
CausalMutation
|
group |
CGI |
|
|
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
1,4-DHP is a potent Voltage-Gated Calcium Channel (VGCC) antagonist derivative which acts as an anti-hypertensive, anti- anginal, anti-tumor, anti-inflammatory, anti-tubercular, anti-cancer, anti-hyperplasia, anti-mutagenic, anti-dyslipidemic, and anti-ulcer agent.
|
31735158 |
2019 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
DPD activity is highly variable in cancer populations, and this variation may influence the antitumor efficacy of 5-fluorouracil.
|
10499634 |
1999 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
DPD is also responsible for the degradation of 5-fluorouracil (5-FU), which is the most frequently prescribed anticancer drug for the treatment of malignancies of the gastrointestinal tract.
|
12851836 |
2003 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
|
30348537 |
2018 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A DPD-deficient phenotype among cancer patients, which has posed a serious problem in 5FU-based chemotherapy, was reported to be in part ascribed to germline mutations in dihydropyrimidine dehydrogenase (DPYD) gene.
|
11267945 |
2001 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A polymorphism that disrupts a putative gamma-interferon response element was identified in a cancer patient with reduced DPD activity and severe 5FU toxicity.
|
10777676 |
2000 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Although normal activity of DPD was observed in fibroblasts, the DPD activity in leucocytes of the cancer patient proved to be in the heterozygous range.
|
9470816 |
1997 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Complete or partial deficiency of DPD activity has been demonstrated to induce severe toxicities in cancer patients treated with fluoropyrimidine therapy.
|
23585145 |
2013 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines.
|
27248859 |
2016 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Deficiency in human DPD is associated with autosomal recessive disease, thymine-uraciluria, and with severe 5-fluorouracil toxicity in cancer patients.
|
16556484 |
2007 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects.
|
14635116 |
2003 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies.
|
27399164 |
2016 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Expression of TS, DPD and OPRT in cancer tissue has been reported to be associated with sensitivity and/or resistance to 5-FU therapy.
|
19288006 |
2009 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
For example, the presence of dihydropyrimidine dehydrogenase gene (DPYD) polymorphisms in cancer patients may lead to adverse effects when adopting fluoropyrimidine-based therapies.
|
28430339 |
2017 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
High grade malignancy is significantly associated with higher expression of TS, OPRT and DPD in thymic epithelial tumors.
|
21550686 |
2011 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Impact of dihydropyrimidine dehydrogenase on 5-fluorouracil treatment in cancer patients.
|
12844478 |
2003 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In 400 patients that were diagnosed with cancer and were eligible for 5-FU treatment, 14 patients were found to be heterozygous for the splice-site mutation DPYD IVS14+1G>A, which corresponds to a population frequency of 3.5%.
|
19822137 |
2010 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition, increased interest has been focused on the biological roles of TS and DPD as the independent prognostic factors as well as responsive determinants for cancer patients with 5-FU based therapy.
|
19697054 |
2010 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In conclusion, the mRNA expression and protein levels of TS, DPD and OPRT differed according to the type of cancer.
|
19020767 |
2008 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Intratumoral DPD mRNA expression level in pancreatic cancer was significantly higher than the other malignancies.
|
18309485 |
2008 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Methylation was detected in five of five DPD-deficient volunteers and in three of five of the DPD-deficient cancer patient samples.
|
16361556 |
2005 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Moreover, breast cancer was characterized by high TS activity and lung cancer by high DPD activity as compared with gastric and colon cancers, and their high activity levels may influence to the effectiveness of 5-fluorouracil against cancers of these organs.
|
14612954 |
2003 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Mutations in DPD-coding gene (DPYD) were shown to increase the risk of severe toxicity in FP-treated cancer patients.
|
19288105 |
2009 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Recently, many clinical studies have demonstrated that UFT is effective for cancer with a low activity of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD).
|
15868929 |
2005 |